Quadrivalent FluMist Clears FDA But Won’t Be On The Market Until 2013
Executive Summary
MedImmune does not expect improved sales of the intranasal vaccine based on the enhanced formulation.
You may also be interested in...
Flu Vaccines Likely To Remain Immune From Comparative Effectiveness
CDC’s Advisory Committee on Immunization Practices adds four recently-approved flu vaccines to its recommended list of products, but the committee chair expresses doubt that there could ever be data to make preferential recommendations.
GSK’s Quad Flu Vaccine Clears FDA; B-Strain Protection Gap Could Drive Adoption
About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.
Four-Strain Flu Vaccine Gains Traction With Sanofi’s sBLA Filing
Sanofi’s application for a quadrivalent flu vaccine comes eight months after FDA approved MedImmune’s quadrivalent and seven months after GSK’s filing; companies expect to transition to the four-strain vaccine.